Illumina Partners with Shenzhen-Based Genomics Firm Haplox to Launch Locally Manufactured Sequencer in China

Source: genomeweb

On December 12, Illumina, Inc. announced that it has partnered with Shenzhen HaploX to launch the China-made sequencer NextSeq 2000Dx-Cn-Hap in China.

"This marks a new phase in the strategic partnership between the two companies," Illumina said in a statement. "In the future, Illumina and HaploX will take the localized manufacturing of high-end life science instruments as a new starting point, focus on scientific research and innovation, and leverage the advantages of the Guangdong-Hong Kong-Macao Greater Bay Area."

HaploX, headquartered in Shenzhen, stated that the company has provided genetic testing services to hundreds of hospitals, biopharmaceutical companies, research institutions, health examination centers, insurance companies, and local governments across China.

The company said it focuses on gene sequencing, liquid biopsy testing, bioinformatics, and big data analysis. Its Shenzhen laboratory has passed CLIA and CAP certification.

In 2018, HaploX completed a $32 million Series A+ financing round, with investors including SB China Venture Capital and CASIC Venture Capital.